Moors & Cabot Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 1.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 183,079 shares of the biopharmaceutical company’s stock after acquiring an additional 1,765 shares during the period. Pfizer accounts for about 1.0% of Moors & Cabot Inc.’s portfolio, making the stock its 14th biggest holding. Moors & Cabot Inc.’s holdings in Pfizer were worth $6,156,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. KLCM Advisors Inc. boosted its stake in Pfizer by 3.6% during the second quarter. KLCM Advisors Inc. now owns 405,626 shares of the biopharmaceutical company’s stock valued at $13,625,000 after buying an additional 14,139 shares during the last quarter. Carret Asset Management LLC boosted its stake in Pfizer by 7.4% during the second quarter. Carret Asset Management LLC now owns 119,500 shares of the biopharmaceutical company’s stock valued at $4,014,000 after buying an additional 8,265 shares during the last quarter. First Commonwealth Financial Corp PA boosted its stake in Pfizer by 35.2% during the second quarter. First Commonwealth Financial Corp PA now owns 10,404 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 2,706 shares during the last quarter. Peapack Gladstone Financial Corp boosted its stake in Pfizer by 3.9% during the second quarter. Peapack Gladstone Financial Corp now owns 199,502 shares of the biopharmaceutical company’s stock valued at $6,701,000 after buying an additional 7,461 shares during the last quarter. Finally, FTB Advisors Inc. boosted its stake in Pfizer by 8.6% during the second quarter. FTB Advisors Inc. now owns 116,364 shares of the biopharmaceutical company’s stock valued at $3,903,000 after buying an additional 9,226 shares during the last quarter. 69.89% of the stock is owned by hedge funds and other institutional investors.

Shares of Pfizer Inc. (PFE) traded up $0.47 during mid-day trading on Tuesday, reaching $36.21. The company’s stock had a trading volume of 14,362,900 shares, compared to its average volume of 19,915,859. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $36.78. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The stock has a market capitalization of $213,035.67, a P/E ratio of 14.30, a PEG ratio of 2.52 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the prior year, the business posted $0.61 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year. equities research analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.53%. Pfizer’s payout ratio is 79.01%.

In other news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

PFE has been the subject of a number of research reports. Cowen set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Jefferies Group set a $35.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Thursday, August 24th. Berenberg Bank reissued a “hold” rating and set a $36.00 price target (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Deutsche Bank set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Goldman Sachs Group set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the stock. Pfizer has an average rating of “Buy” and a consensus target price of $38.77.

TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/pfizer-inc-pfe-stake-boosted-by-moors-cabot-inc/1759799.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.